Table 2 Top five IPA canonical pathways modulated by rSS1GFP and rSS1GFP-M/NLSm
Time points (hpi) | Virus | IPA canonical pathwaya | P value | Gene countb |
|---|---|---|---|---|
6 | rSS1GFP | Toll-like receptor signaling pathway | 3.62E−04 | 3/10 |
RIG-I-like receptor signaling pathway | 4.15E−04 | 1/8 | ||
NF-kappa B signaling pathway | 2.18E−03 | 2/8 | ||
Hepatitis C | 3.70E−03 | 2/12 | ||
TGF-β signaling pathway | 4.53E−03 | 1/6 | ||
rSS1GFP-M/NLSm | Apelin signaling pathway | 2.15E−03 | 0/2 | |
Hippo signaling pathway | 3.44E−03 | 1/5 | ||
Pyrimidine metabolism | 1.35E−02 | 0/3 | ||
12 | rSS1GFP | Cytokine–cytokine receptor interaction | 8.93E−10 | 8/12 |
HTLV-1 infection | 2.06E−9 | 9/21 | ||
Kaposi sarcoma-associated herpesvirus infection | 6.38E−9 | 10/32 | ||
Transcriptional misregulation in cancer | 2.28E−8 | 4/7 | ||
TNF signaling pathway | 3.80E−7 | 6/16 | ||
rSS1GFP-M/NLSm | Thyroid hormone signaling pathway | 3.63E−5 | 3/13 | |
Biosynthesis of amino acids | 4.96E−5 | 1/8 | ||
Rap1 signaling pathway | 2.11E−4 | 3/8 | ||
Glycine, serine and threonine metabolism | 2.25E−3 | 2/10 | ||
Non-small cell lung cancer | 2.63E−3 | 1/9 | ||
18 | rSS1GFP | MAPK signaling pathway | 1.01E−11 | 21/42 |
TNF signaling pathway | 2.70E−10 | 12/36 | ||
MAPK signaling pathway | 6.99E−9 | 9/23 | ||
Human papillomavirus infection | 1.38E−8 | 10/21 | ||
Transcriptional misregulation in cancer | 3.31E−8 | 15/38 | ||
rSS1GFP-M/NLSm | DNA replication | 1.09E−4 | 6/44 | |
Neurotrophin signaling pathway | 1.51E−3 | 4/23 | ||
Cellular senescence | 2.36E−3 | 3/26 | ||
Insulin resistance | 4.15E−2 | 2/15 | ||
Caffeine metabolism | 7.38E−2 | 2/12 |